About AminoChain
AminoChain is a Healthcare company based in New York (United States) founded in 2022 by Caspar Barnes. It operates as an a blockchain-based platform for tokenizing and incentivizing stem cell donations. AminoChain has raised $7.07 million across 1 funding round from investors including Andreessen Horowitz. Its chief executive is Caspar Barnes. AminoChain offers products and services including AminoChain Platform and Specimen Center. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its competitors include GenVault Corporation, iSpecimen, Cryoniss, PrecisionMed and ViaCell and 2 more; 4 of its 7 listed competitors have raised funding.
Company details
AminoChain was founded in 2022 in New York, United States, within the blockchain and biotechnology sectors. A decentralized platform is operated to tokenize stem cell donations and provide incentives for donors. Connections are facilitated between biobanks, clinical sites, and bio-pharma companies via a bio-sample marketplace. Emphasis is given to secure tokenization processes and donor participation mechanisms.
- Headquarters New York, United States
- Founders Caspar Barnes
- SectorsHealthcare
- Email••••••••
- Website aminochain.io
- Social LinkedIn X
- Total Equity Funding$7.07M (USD)
in 1 rounds
- Latest Funding Round$7.07M (USD), Series A
Aug 2024
- Investors
Products & Services of AminoChain
AminoChain offers a comprehensive portfolio of products and services, including AminoChain Platform and Specimen Center.
Technology connecting stakeholders for biospecimen donation and tracking.
Platform for discovering and acquiring biospecimens for research needs.
Funding Insights of AminoChain
AminoChain has successfully raised a total of $7.07M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.07 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.07M
- Total Rounds 1
- Last Round Series A — $7.07M
- First Round $7.07M
(Aug 2024)
- Investors Count 1
All 1 funding rounds of AminoChain with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $7.07M | Series A | – | a16z | – |
1 investors in total: 1 institutional.
Investors in AminoChain
AminoChain has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | – | a16z.com | - |
Investor details for AminoChain
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AminoChain
1 people are tracked at AminoChain (1 in leadership).
| Name | Role | Group |
|---|---|---|
Caspar Barnes | Founder & CEO | Leadership |
Complete people profiles for AminoChain
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AminoChain
2 dated milestones of AminoChain across 2 years, from founding to its latest funding, stage changes and deals.
- Founded AminoChain is founded.
- Funding First funding round of $7.1M.
Competitors of AminoChain
AminoChain has 7 listed competitors in our database, 4 of them funded. They include GenVault Corporation, iSpecimen, Cryoniss, PrecisionMed and ViaCell, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genvault.com | 2000 | Carlsbad, United States | $47.8M | – | Biosamples are stabilized, transported, stored, and retrieved by GenVault. | |
| ispecimen.com | 2009 | Lexington, United States | $11.86M | 75 | Provider of a biorepository of human clinical specimens | |
| cryoniss.com | 2018 | Macclesfield, United Kingdom | $683,055 | 9 | Provider of biobanking services for life sciences industries | |
| precisionmed.com | 1996 | San Diego, United States | – | – | Human biological materials for research are supplied via a biorepository. | |
| viacellinc.com | 1994 | Cambridge, United States | $63M | – | Provider of services for collecting and preserving umbilical cord blood stem cells | |
| cryoportinc.com | 2019 | Brentwood, United States | – | 1,170 | Supply chain solutions for cell and gene therapies are provided. | |
| clean-cells.com | 2000 | Bouffere, France | – | – | Offers cell banking and virus banking services |
Detailed competitors of AminoChain
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AminoChain
The website of AminoChain (aminochain.io) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 28% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as AminoChain (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aminochain
Complete news archive for AminoChain
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AminoChain
AminoChain was founded in 2022 and raised its 1st funding round 2 years after it was founded.
AminoChain is headquartered in New York, United States. It is registered at New York, New York, United States.
Caspar Barnes is the current CEO of AminoChain. They have also founded this company.
AminoChain is a funded company, having raised a total of $7.07M across 1 funding round to date. The company's 1st funding round was a Series A of $7.07M, raised on Aug 2024.
AminoChain was founded in 2022 in New York, United States, within the blockchain and biotechnology sectors. A decentralized platform is operated to tokenize stem cell donations and provide incentives for donors. Connections are facilitated between biobanks, clinical sites, and bio-pharma companies via a bio-sample marketplace. Emphasis is given to secure tokenization processes and donor participation mechanisms.
AminoChain's top competitors include Cryoport, iSpecimen and Clean Cells.
AminoChain offers AminoChain Platform and Specimen Center.
AminoChain has 1 investor. Key investors include Andreessen Horowitz.